Expression And Correlation Of GPR30 And EGFR In Endometrial Adenocarcinoma And Its Clinical Significance

Objective:To investigate the expression and correlation of GRP30 and EGFR in endometrial adenocarcinoma, and to explore the relationship between them and the prognosis of the patients with endometrial adenocarcinoma, we expected that the study will help us to elucidate whether the two involved in regulation of proliferation of endometrial carcinoma and to provide novel therapeutic targets for clinical treatment of endometrial carcinoma.Methods:The expression of GPR30 and EGFR in 20 cases of normal endometrium,20 cases of endometrial atypical hyperplasia (EAH group) and 50 cases of endometrial adenocarcinoma (EAC group) tissues were detected by immunohistochemical EliVision two-stages method. The statistical analysis methods of data:the count materials were evaluated withχ2 test or Fisher probabilities in 2×2 table; the grade materials were evaluated with nonparametric rank sum test (Mann-Whitney U test or Kruskal-Wallis H test); the correlation using Spearman rank correlation analysis; the calculation of cumulative survival rates in patients using Kaplan-Meier statistic; and the cumulative survival curves were examined by means of the Log-Rank test.Results:(1)The expression rates of GPR30 in normal endometrium, EAH and EAC tissues were 10.0%,45.0% and 74.0%, respectively, showing a gradually rising trend. The positive expression rate and expression intensity of GPR30 in EAC group was significantly higher than that in EAH group or normal group (P<0.05; P<0.001, respectively), its positive expression rate and expression intensity in EAH group also was higher than that in the normal group (P<0.05). In the EAC group, the GPR30 expression correlated with histological grade, the worse tumor differentiation, the higher the rate of positive expression (P<0.05), but its expression did not correlate with any other clinicopathological parameters else(P>0.05).(2)The expression rates of EGFR in normal endometrium, EAH and EAC tissues were 30.0%,40.0% and 70.0%, respectively, showing a rising trend. The positive expression rate and expression intensity of EGFR in EAC group was significantly higher than that in EAH group or normal group (P<0.05; P<0.001, respectively), but the difference of that between EAH group and normal group were no statistical significance (P>0.05). In the EAC group, EGFR positive expression intensity correlated with FIGO stage, histopathological grade or tumor diameter (P<0.05, respectively), EGFR expression intensity of stageⅢwas significantly higher than that of stageⅠ(P<0.05), but its expression intensity of stageⅡwere not different from that of stageⅠor stageⅢ(P>0.05, respectively), combining stageⅠand stageⅡ, EGFR expression intensity of stageⅢwas significantly higher than that of stageⅠ+stageⅡgroup(P<0.05); EGFR expression in G2 group or G3 group was significantly higher than that in G1 group (P<0.05, respectively), but comparing the G2 group with the G3 group, EGFR positive expression intensity were not significant different (P>0.05), combining G2 group and G3 group, its expression intensity in G1 group was significantly lower than that in G2 +G3 group (P<0.05); EGFR were overexpression more frequently in cases with measurements more than 4cm in diameter(P<0.05); its expression did not correlate with any other clinicopathological parameters else(P>0.05).(3)Positively correlation between the expression of GPR30 and that of EGFR was observed in EAC group (r=0.308, P<0.05).(4)The 5-year cumulative survival rate of stageⅢEAC patients was significantly lower than that of stageⅠ/ⅡEAC patients, the difference was statistical significance (P<0.001).(5)In patients with EAC, the 5-year cumulative survival rate of high GPR30 expression group was significantly lower than that of the low expression group (P<0.05). Combining with FIGO stage, the 5-year cumulative survival rate of stageⅠ/Ⅱ,low GPR30 expression group was higher than that of the stageⅠ/Ⅲ,high GPR30 expression group (P<0.05), and that of stageⅢ,high GPR30 expression was lower than the stageⅠ/Ⅱ,low or high GPR30 expression group (P<0.001; P<0.05, respectively), comparing stageⅢ,high and low GPR30 expression groups, although lower survival rate, there was no statistical significant difference (P>0.05). (6)In patients with EAC, the 5-year cumulative survival rate of low EGFR expression group was significantly higher than that of the high expression group (P<0.05). Combining with FIGO stage, the 5-year cumulative survival rate of stageⅠ/Ⅱ,low EGFR expression group was higher than that of the high expression group (P<0.05); and that of stageⅢ,high EGFR expression group was lower than that of the stageⅠ/Ⅱ,low EGFR expression group (P<0.001), although the 5-year cumulative survival rate of stageⅢ,high EGFR expression group was lower than that of the stageⅢ,low EGFR expression group or stageⅠ/Ⅱ,high EGFR expression group, there were no statistical significant difference (P>0.05, respectively).Conclusions:The results suggested that GPR30 and EGFR over-expression may be related to the process of occurrence and development of endometrial adenocarcinoma. GPR30 and EGFR expression in endometrial adenocarcinoma was positively correlated with each other, there could be interactions between the two. The expression levels of GPR30 and EGFR might predict good or poor survival in patients with endometrial adenocarcinoma. GPR30 and EGFR could become more effective novel clinical therapeutic targets in patients with endometrial adenocarcinoma.